This is a working overview of Angiotensin IV analog, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-21. Anything still debated is marked as such rather than presented as settled.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical for lyophilized peptide-like research chemicals. |
| Solubility | Limited in water; soluble in some organic solvents | DMSO is commonly used for stock solutions. |
| Typical storage | -20 °C or below, desiccated, protected from light | Avoid repeated freeze-thaw cycles. |
| Purity assessment | Reverse-phase HPLC with UV detection | Mass spectrometry is often used for identity confirmation. |
| Common document | Certificate of analysis | Batch-specific; does not establish safety or efficacy. |
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Optical spectrometry, a technique for measuring the distribution of light across the optical spectrum, from the ultraviolet spectral region to the visible and infrared Ion-mobility spectrometry, an analytical technique used to separate and identify ionized molecules in the gas phase based on their ion mobility in a carrier buffer gas Mass spectrometry, an analytical technique that measures the mass-to-charge ratio of charged particles Rutherford backscattering spectrometry, an analytical technique used to determine the structure and composition of materials by measuring the back-scattering of a beam of high energy ions impinging on a sample Neutron triple-axis spectrometry, a technique used in inelastic neutron scattering Gamma-spectrometry, a method used to acquire a quantitative gamma-spectrum measurement Nuclear magnetic resonance spectroscopy, a technique that uses radio frequency pulses and a magnetic field to study the properties of atomic nuclei.
=== Example: Azathioprine Therapy === Azathioprine is an immunomodulator for inflammatory bowel disease, for instance. Its metabolite relies on two different enzymes (TPMT and NUDT15) to eliminate its effect on our body during its metabolism. If the patient has the phenotype of the enzymes that metabolize it poorly, i.e., the poor metabolizer, more toxic metabolites are accumulated in the body. Thus, the patient has a greater risk of the related side-effect. The side effect causes the adjustment of dosage or switching to another drug.
The JWP considered that the JINR–LLNL collaborations of 2004 and 2007, producing element 113 as the daughter of element 115, did not meet the discovery criteria as they had not convincingly determined the atomic numbers of their nuclides through cross-bombardments, which were considered necessary since their decay chains were not anchored to previously known nuclides. They also considered that the previous JWP's concerns over their chemical identification of the dubnium daughter had not been adequately addressed. The JWP recognised the JINR–LLNL–ORNL–Vanderbilt collaboration of 2010 as having discovered elements 117 and 115, and accepted that element 113 had been produced as their daughter, but did not give this work shared credit. After the publication of the JWP reports, Sergey Dimitriev, the lab director of the Flerov lab at the JINR where the discoveries were made, remarked that he was happy with IUPAC's decision, mentioning the time Riken spent on their experiment and their good relations with Morita, who had learnt the basics of synthesising superheavy elements at the JINR. The sum argument advanced by the JWP in the approval of the discovery of element 113 was later criticised in a May 2016 study from Lund University and the GSI, as it is only valid if no gamma decay or internal conversion takes place along the decay chain, which is not likely for odd nuclei, and the uncertainty of the alpha decay energies measured in the 278113 decay chain was not small enough to rule out this possibility.
On March 1, 2013, it was announced that trace amounts of horse meat from a European supplier had been found in various food products, including Taco Bell's beef in the UK. By August 2017, there were 17 Taco Bell branches in the United Kingdom, all of which were in England and outside of London. The first Scottish branch was opened in Glasgow in December 2017. As of June 2019 there are 39 branches in Scotland and England, including three in London. Beginning in October 2019, Taco Bell locations in the UK began serving Doritos Locos Tacos. On March 2, 2020, the first Welsh Taco Bell branch was opened in Cardiff. More recently, in November 2021, Taco Bell opened its 77th UK store, and a return to the British Midlands with a store in The Royal Town of Sutton Coldfield, Birmingham. In August 2022 a Taco Bell was opened in Torquay, Devon, the second in the county after Plymouth. As of 2024 there are now more than 130 locations in the UK.
Sources: en.wikipedia.org
The gamma-emitting isotopes iodine-123 (half-life 13.223 hours), and (less commonly) the longer-lived and less energetic iodine-125 (half-life 59.392 days) are used as nuclear imaging tracers to evaluate the anatomic and physiologic function of the thyroid. Abnormal results may be caused by disorders such as Graves' disease or Hashimoto's thyroiditis. Both isotopes decay by electron capture (EC) to the corresponding tellurium nuclides, but in neither case are these the metastable nuclides 123mTe and 125mTe (which are of higher energy, and are not produced from radioiodine). Instead, the excited tellurium nuclides decay immediately (half-life too short to detect). Following EC, the excited 123Te from 123I emits a high-speed 127 keV internal conversion electron (not a beta ray) about 13% of the time, but this does little cellular damage due to the nuclide's short half-life and the relatively small fraction of such events. In the remainder of cases, a 159 keV gamma ray is emitted, which is well-suited for gamma imaging. Excited 125Te resulting from electron capture of 125I also emits a much lower-energy internal conversion electron (35.5 keV), which does relatively little damage due to its low energy, even though its emission is more common. The relatively low-energy gamma from 125I/125Te decay is poorly suited for imaging, but can still be seen, and this longer-lived isotope is necessary in tests that require several days of imaging, for example, fibrinogen scan imaging to detect blood clots.
H1299, also known as NCI-H1299 or CRL-5803, is a human non-small cell lung carcinoma cell line derived from the lymph node, which is widely used in research. As with other immortalized cell lines, H1299 cells can divide indefinitely. These cells have a homozygous partial deletion of the TP53 gene and as a result, do not express the tumor suppressor p53 protein which in part accounts for their proliferative propensity. These cells have also been reported to secrete the peptide hormone neuromedin B (NMB), but not gastrin-releasing peptide (GRP).
== Name == The Socialist Republic of Bosnia and Herzegovina was formed during a meeting of the State Anti-fascist Council for the National Liberation of Bosnia and Herzegovina (ZAVNOBiH) in Mrkonjić Grad on 25 November 1943. In April 1945, its name was formalized as the Federated State of Bosnia and Herzegovina (Serbo-Croatian: Federalna Država Bosna i Hercegovina / Федерална Држава Босна и Херцеговина), a constituent unit of the Democratic Federal Yugoslavia. With DF Yugoslavia changing its name to the Federal People's Republic of Yugoslavia on 29 November 1945 as well as the promulgation of the 1946 Yugoslav Constitution two months later in January, its constituent units also changed their respective names. FS Bosnia and Herzegovina thus became known as the People's Republic of Bosnia and Herzegovina (Narodna Republika Bosna i Hercegovina / Народна Република Босна и Херцеговина). This constitutional system lasted until the 1963 Yugoslav Constitution. On 7 April 1963, Yugoslavia was reconstituted as the Socialist Federal Republic of Yugoslavia, and PR Bosnia and Herzegovina changed its name to the Socialist Republic of Bosnia and Herzegovina (Socijalistička Republika Bosna i Hercegovina / Социјалистичка Република Босна и Херцеговина). After independence on 1 March 1992, the country was renamed to the Republic of Bosnia and Herzegovina. Following the Dayton Agreement that was in force, it became simply a federated state known as Bosnia and Herzegovina in 1997.
Sources: en.wikipedia.org
=== Nomenclature === Standardized GST nomenclature first proposed in 1992 identifies the species to which the isozyme of interest belongs with a lower-case initial (e.g., "h" for human), which precedes the abbreviation GST. The isozyme class is subsequently identified with an upper-case letter (e.g., "A" for alpha), followed by an Arabic numeral representing the class subfamily (or subunit). Because both mitochondrial and cytosolic GSTs exist as dimers, and only heterodimers form between members of the same class, the second subfamily component of the enzyme dimer is denoted with a hyphen, followed by an additional Arabic numeral. Therefore, if a human glutathione S-transferase is a homodimer in the pi-class subfamily 1, its name will be written as "hGSTP1-1." The early nomenclature for GSTs referred to them as Y proteins, referring to their separation in the Y fraction (as opposed to the "X and Z" fractions) using Sephadex G75 chromatography. As GST sub-units were identified they were referred to as Ya, Yp, etc. with if necessary, a number identifying the monomer isoform (e.g. Yb1). Litwack et al proposed the term Ligandin to cover the proteins previously known as Y proteins. In clinical chemistry and toxicology, the terms alpha GST, mu GST, and pi GST are most commonly used.
== Side effects == Skin lightening creams have commonly contained mercury, hydroquinone, and corticosteroids. Because these compounds can induce both superficial and internal side effects, they are illegal to use and market in multiple nations. However, various chemical studies indicate that these compounds continue to be used in sold cosmetic products, though they are not explicitly declared as ingredients. Prolonged usage of mercury-based products can ultimately discolor the skin, as mercury will accumulate within the dermis. Mercury toxicity can cause acute symptoms such as pneumonitis and gastric irritation. However, according to a study by Antoine Mahé and his colleagues, mercurial compounds can also contribute to long-term renal and neurological complications, the latter of which includes insomnia, memory loss, and irritability. Other studies have explored the impact of hydroquinone exposure on health. Hydroquinone rapidly absorbs into the body via dermal contact; long-term usage has been found to cause nephrotoxicity and benzene-induced leukemia in the bone marrow. A study by Pascal del Giudice and Pinier Yves indicated that hydroquinone usage is strongly correlated with the development of ochronosis, cataracts, patchy depigmentation, and contact dermatitis. Ochronosis can lead to lesions and squamous cell carcinomas. While hydroquinone has not been officially classified as a carcinogen, it can metabolize into carcinogenic derivatives and induce genetic changes in the form of DNA damages.
Within a few months of his joining the Committee, what had previously been an innovative and forward-looking group became riven with strife. It was strictly Lindemann versus the rest, with his hostility to radar and his insistence on totally impractical ideas about intercepting enemy aircraft by means of wires dangled from balloons, or by infrared, which at that time simply did not have the sensitivity to detect aircraft at long range. Churchill's backing meant the other members' complaints about his behaviour were ignored. The matter was eventually referred back to Lord Swinton, the new Secretary of State for Air. Swinton solved the problem by dissolving the original Committee and reforming it with Appleton in Lindemann's place. As the development effort grew, Watt requested a central research station be established "of large size and with ground space for a considerable number of mast and aerial systems". Several members of the team went on scouting trips with Watt to the north of Orfordness but found nothing suitable. Then Wilkins recalled having come across an interesting site about 10 mi (16 km) south of Orfordness, some time earlier while on a Sunday drive. He recalled it because it was some 70–80 ft (21–24 m) above sea level, which was unusual in that area. The large manor house on the property would have ample room for experimental labs and offices. In February and March 1936, the team moved to Bawdsey Manor and established the Air Ministry Experimental Station (AMES). When the scientific team left in 1939, the site became the operational CH site RAF Bawdsey.
Sources: en.wikipedia.org
Dry powder is usually kept frozen, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data for dihexa are limited, so general peptide storage practices are commonly used.
Reverse-phase HPLC is commonly used to estimate purity, and mass spectrometry helps confirm molecular identity. Certificates of analysis may summarize these results. Independent testing can provide additional verification when standards are unavailable.
In many countries, dihexa is not approved as a medicine and is sold only for research purposes. Regulations differ by jurisdiction, and import or possession rules may apply. Buyers should confirm local legal status before obtaining it.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.